Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)

Aim. This study compared the effects of telmisartan and losartan on nonalcoholic fatty liver disease (NAFLD) and biochemical markers of insulin resistance in hypertensive NAFLD patients with type 2 diabetes mellitus. Methods. This was a randomized, open-label, parallel-group comparison of therapy wi...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Endocrinology 2013-01, Vol.2013 (2013), p.120-128-116
Main Authors: Kawai, Toshihide, Tomita, Kengo, Hirata, Takumi, Yokoyama, Hirokazu, Shimada, Akira, Kikuchi, Masahiro, Hirose, Hiroshi, Ebinuma, Hirotoshi, Irie, Junichiro, Ojiro, Keisuke, Oikawa, Yoichi, Saito, Hidetsugu, Itoh, Hiroshi, Hibi, Toshifumi
Format: Article
Language:English
Subjects:
Alcohol
Antibodies
Antihypertensives
Blood pressure
Cholesterol
Chromatography
Clinical Study
Diabetes
Dosage and administration
Drug therapy
Endocrinology
Fasting
Glucose
Health aspects
Hepatitis
Homeostasis
Hypertension
Insulin resistance
Liver diseases
Losartan
Metabolic syndrome
Patients
Plasma
Spleen
Telmisartan
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim. This study compared the effects of telmisartan and losartan on nonalcoholic fatty liver disease (NAFLD) and biochemical markers of insulin resistance in hypertensive NAFLD patients with type 2 diabetes mellitus. Methods. This was a randomized, open-label, parallel-group comparison of therapy with telmisartan or losartan. Nineteen hypertensive NAFLD patients with type 2 diabetes were randomly assigned to receive telmisartan at a dose of 20 mg once a day (n=12) or losartan at a dose of 50 mg once a day (n=7) for 12 months. Body fat area as determined by CT scanning and hepatic fat content based on the liver-to-spleen (L/S) ratio, as well as several parameters of glycemic and lipid metabolism, were compared before and after 12 months. Results. The telmisartan group showed a significant decline in serum free fatty acid (FFA) level (from 0.87±0.26 to 0.59±0.22 mEq/L (mean ± SD), P=0.005) and a significant increase in L/S ratio (P=0.049) evaluated by CT scan, while these parameters were not changed in the losartan group. Conclusion. Although there was no significant difference in improvement in liver enzymes with telmisartan and losartan treatment in hypertensive NAFLD patients with type 2 diabetes after 12 months, it is suggested that telmisartan may exert beneficial effects by improving fatty liver.Erratum to “Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)”dx.doi.org/10.1155/2014/302602
ISSN:1687-8337
1687-8345
DOI:10.1155/2013/587140